BioCurity Pharmaceuticals: Funding, Investors & Team (Sep 2026)

BioCurity Pharmaceuticals is a biopharmaceutical company with a mission to transform a cancer patient’s recovery, by addressing a global unmet need for an effective treatment to mitigate radiation therapy toxicity. It is on track to fundamentally change the course of radiation therapy for cancer patients, worldwide. Approximately 6 million of the 18 million people who will be diagnosed with cancer every year, will receive radiation treatment. The lack of an effective treatment for the adverse side effects associated with radiation therapy represents a substantial market opportunity, but most importantly, a chance to help better the quality of life for cancer survivors around the world. BioCurity’s patented technologies and drugs in their pipeline have the potential to significantly reduce radiation toxicity, not just for newly diagnosed patients, but also for the millions of patients who must receive radiation as a part of their ongoing treatment for cancer.

BioCurity Pharmaceuticals has raised $80k across 1 round on record. The most recent is a Seed of $80k announced in Apr 2022.

BioCurity Pharmaceuticals' most recent funding round on record is a Seed of $80k, announced in Apr 2022.

FundedIQ lists Cheryl Baker (Founder) at BioCurity Pharmaceuticals.

BioCurity Pharmaceuticals is based in Jupiter, Florida, United States.

BioCurity Pharmaceuticals is in the 1-10 employee band.

BioCurity Pharmaceuticals' latest round of $80k is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.